secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImmunityBio, Inc. (IBRX)
CIK:        0001326110
Form:       8-K
Filed at:   2024-12-10T23:59:59+00:00
Accession:  0001193125-24-274438
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmunityBio announces public offering and $505M debt restructuring with Nant Capital
--------------------------------------------------------------------------------

- Proposed public offering of common stock; Jefferies & Piper Sandler lead; 30-day option for 15% additional shares.
- Contingent on offering, Nant Capital converts $230M notes into ~116.5M shares; remaining $505M note due 2027 at SOFR+8%.
- Enters Limited Consent and Amendment to Revenue Interest Purchase Agreement with Oberland consenting to restructuring.
- Shareholder derivative action filed Nov 20, 2024 in Delaware Chancery challenging Sept 2023 financing with Dr. Soon-Shiong.
- Net proceeds to fund ANKTIVA commercialization, BCG-naïve NMIBC and NSCLC trials, and working capital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326110/000119312524274438/0001193125-24-274438-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326110/000119312524274438/d883742d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-274438

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer